What is LTR PHARMA FPO [LTP]'s (LTP.AX) StockRank?

MoatMap's StockRank for LTR PHARMA FPO [LTP] (LTP.AX) is 6/100, with a Strong Sell signal. This is a composite score combining Quality (30), Value (27), and Momentum (23) factor ranks across MoatMap's 20,000+ stock universe.

Does LTR PHARMA FPO [LTP] have an economic moat?

LTR PHARMA FPO [LTP] (LTP.AX) has a Quality factor score of 30/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is LTR PHARMA FPO [LTP] a buy, hold, or sell?

MoatMap's current signal for LTR PHARMA FPO [LTP] (LTP.AX) is Strong Sell, based on a StockRank of 6/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is LTR PHARMA FPO [LTP] in?

LTR PHARMA FPO [LTP] (LTP.AX) operates in the Healthcare sector, specifically the Biotechnology industry (Australia).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

LTP.AX

STRONG SELL

LTR PHARMA FPO [LTP] · Healthcare · Australia · $71M · Avg Vol: $211K/d

StockRank

P/E (TTM)

—

ROE

-29.3%

D/E

—

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

COMPANY DESCRIPTION

LTR Pharma Limited is an innovative biotechnology company focused on improving men's health through the development of rapid-acting intranasal drug delivery systems. Its lead product, Spontan, is a nasal spray formulation of a PDE5 inhibitor designed to treat erectile dysfunction significantly faster than traditional oral tablets. The company's competitive moat is established through its proprietary formulation technology and a streamlined regulatory pathway targeting a highly lucrative global market.

PRICE (1Y)+39.5%

SMA 50SMA 200

$0.40

RSI (14)

69.7

52W High

$0.57

From 52W High

0.7%

SCORE BREAKDOWN

Quality

ROIC

-17.8%29.4

ROE

-29.3%25.8

GP/Assets

-10.5%6.6

Op. Margin

-8230.9%2.5

FCF/Assets

-13.9%23.6

Piotroski

238.9

Int. Cover

-50.0x6.0

D/E Ratio

—N/A

Current Ratio

57.47x99.4

Value

P/E (TTM)

—N/A

EV/EBITDA

-4.8x25.0

P/FCF

—N/A

P/B

2.7x47.9

P/S

63.5x9.3

Div Yield

—N/A

Momentum

52W High %

70%20.9

RS 6M

15%N/A

SMA 50/200

0.86x18.5

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$71M

P/E (Forward)

—

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LTP.AX are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
LTP.AX	LTR PHARMA FPO [LTP](you)	$71M	6	STRONG SELL
ILA.AX	Island Pharmaceuticals Limited	$76M	3	STRONG SELL
PAR.AX	Paradigm Biopharmaceuticals Limited	$70M	0	STRONG SELL
IMM.AX	Immutep Limited	$54M	5	STRONG SELL
ACW.AX	Actinogen Medical Limited	$87M	9	STRONG SELL
NYR.AX	Nyrada Inc.	$79M	1	STRONG SELL
DXB.AX	Dimerix Limited	$92M	1	STRONG SELL
ATH.AX	Alterity Therapeutics Limited	$90M	15	STRONG SELL
OCC.AX	Orthocell Limited	$146M	14	STRONG SELL
RAC.AX	Racura Oncology Ltd	$330M	10	STRONG SELL

Peer medians: ROE -18.2% · P/E 21.1x · Gross margin 49.7%

LTR PHARMA FPO [LTP] (LTP.AX) — Stock Score Summary

LTR PHARMA FPO [LTP] (LTP.AX) has a MoatMap StockRank of 6/100 based on Quality (30/100), Value (27/100), and Momentum (23/100) factor scores. The current signal is STRONG SELL.

Key Financial Metrics

Price	$0.40
Market Cap	$71M
Price/Book	2.67
Return on Equity	-29.3%
Return on Invested Capital	-17.8%
Gross Margin	0.0%
Operating Margin	-8230.9%
Revenue Growth	-83.6%
Free Cash Flow	$-2M

LTR PHARMA FPO [LTP] operates in the Biotechnology industry, part of the Healthcare sector (Australia).

Frequently Asked Questions

What is LTR PHARMA FPO [LTP]’s (LTP.AX) StockRank?: MoatMap’s StockRank for LTR PHARMA FPO [LTP] (LTP.AX) is 6/100, with a Strong Sell signal. It is a composite of Quality (30), Value (27), and Momentum (23) factor ranks across MoatMap’s 20,000+ stock universe.
Does LTR PHARMA FPO [LTP] have an economic moat?: LTR PHARMA FPO [LTP] (LTP.AX) has a Quality factor score of 30/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is LTR PHARMA FPO [LTP] a buy, hold, or sell?: MoatMap’s current signal for LTR PHARMA FPO [LTP] (LTP.AX) is Strong Sell, based on a StockRank of 6/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is LTR PHARMA FPO [LTP] in?: LTR PHARMA FPO [LTP] (LTP.AX) operates in the Healthcare sector, specifically the Biotechnology industry (Australia).